Efficacy of Scallop-derived PLASMALOGEN on Parkinson’s patients
Parkinson’s disease is a brain disorder that affects movement. It is the second most common neurodegenerative disease after Alzheimer’s disease. This progressive disorder affects nerve cells in the brain, known as dopamine-producing neurons which are responsible for body movement. When these cells die, symptoms such as tremor, stiffness, difficulty with walking, balance and coordination develop. The Parkinson’s symptoms typically develop gradually and worsen over time. As the disease progresses, Parkinson’s patients may have difficulty walking and talking. They may also experience mental and behavioural changes, memory loss, sleep disorder and depression. Levodopa (also known as L-DOPA) is the most commonly prescribed medicine for Parkinson’s disease. This medicine enters the brain and is converted to dopamine. It helps to manage Parkinson’s symptoms, particularly stiff, rigid body parts and slow movements. Nonetheless, non-motor symptoms of Parkinson’s disease, including sleep disorder, memory loss and depression could not be well controlled with the medicinal treatment but plasmalogen restoration could help to manage the non-motor symptoms.
Besides Alzheimer’s, decreased plasmalogens are also reported in the brain and blood of Parkinson’s patients. In a clinical trial, the efficacy of oral administration of Scallop-derived PLASMALOGEN to non-motor symptoms of Parkinson’s disease was evaluated. In this test, 10 Parkinson’s patients were orally administered 1000 µg (500 µg twice a day) Scallop-derived PLASMALOGEN daily for 24 weeks. Their blood plasmalogen levels and clinical symptoms were determined at 0, 4, 12, 24 and 28 weeks. The last 4 weeks (24 to 28 weeks) was the observational period without any oral administration of plasmalogen. After 24 weeks of oral administration, plasmalogen levels in blood were raised to almost normal levels. Additionally, some of the clinical symptoms of Parkinson’s disease were also improved, as evaluated using Parkinson’s Disease Questionnaire-39 (PDQ-39). PDQ-39 covers 8 areas: mobility, activities of daily living (ADL), emotional wellbeing, stigma, social support, cognition, communication and body discomfort. Lower scores indicate better health-related quality of life.
Oral administration of Scallop-derived PLASMALOGEN improved blood plasmalogen levels of Parkinson’s patients
Oral administration of Scallop-derived PLASMALOGEN improved clinical symptoms of Parkinson’s patients